Literature DB >> 11369074

Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head and neck mucosal site treated with radiation therapy with palliative intent.

H S Erkal1, W M Mendenhall, R J Amdur, D B Villaret, S P Stringer.   

Abstract

Minimal information has been published about the results of palliative irradiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Forty patients with this diagnosis were treated at the University of Florida with radiation therapy with palliative intent. The nodal response rate was 65% and the symptomatic response rate was 57% at 1 year. The absolute survival rate was 25% at 1 year, as was the cause-specific survival rate. Radiotherapy successfully palliates more than half of those treated. Approximately one fourth are alive 1 year after irradiation.

Entities:  

Mesh:

Year:  2001        PMID: 11369074     DOI: 10.1016/s0167-8140(01)00282-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy.

Authors:  Candan Demiroz; Jeffrey M Vainshtein; Georgios V Koukourakis; Orit Gutfeld; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Matthew J Schipper; Jonathan B McHugh
Journal:  Head Neck       Date:  2013-11-18       Impact factor: 3.147

Review 2.  Diagnosis and management of neck metastases from an unknown primary.

Authors:  L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

3.  Management of neck metastases of unknown primary origin united in two European centers.

Authors:  Jos Straetmans; Julia Vent; Martin Lacko; Ernst-Jan Speel; Christian Huebbers; Robert Semrau; Frank Hoebers; Zlatan Mujagic; Jens-Peter Klussmann; Simon F Preuss; Bernd Kremer
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-11       Impact factor: 2.503

4.  Management of lymph node metastases from an unknown primary site to the head and neck (Review).

Authors:  Shi Min Zhuang; Xi-Fu Wu; Jing-Jia Li; Ge-Hua Zhang
Journal:  Mol Clin Oncol       Date:  2014-07-29

5.  Metastatic squamous cell carcinoma neck with occult primary: A retrospective analysis.

Authors:  Pragya Shukla; Deepak Gupta; Shyam Singh Bisht; Mohan Chand Pant; Madan Lal Bhatt; Kirti Srivastava; Mahendra Pal Singh Negi
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

Review 6.  Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP.

Authors:  Nicholas Pavlidis; George Pentheroudakis; George Plataniotis
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

7.  Management of unresectable head and neck cancers - a retrospective analysis at a rural medical college of India.

Authors:  Aloke Ghosh Dastidar; Somnath Saha; Abhishekh Srivastava; Debdulal Chakroborty; Balaram Sardar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-06-04

8.  Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience.

Authors:  Saikat Das; Solly Thomas; Suparna Kanti Pal; Rajesh Isiah; Subhashini John
Journal:  Indian J Palliat Care       Date:  2013-05

9.  Conventional Fractionation versus Quad Shot in Advanced Head-and-Neck Cancers: A Randomized Controlled Trial.

Authors:  Akansha Choudhary; Ajay Gupta
Journal:  Indian J Palliat Care       Date:  2019 Oct-Dec

10.  Patient-Reported Outcomes Assessing the Impact of Palliative Radiotherapy on Quality of Life and Symptom Burden in Head and Neck Cancer Patients: A Systematic Review.

Authors:  Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.